Abstract Number: 013 • 2020 Pediatric Rheumatology Symposium
A Preliminary Data-driven Anatomic Classification for Childhood Takayasu Arteritis (cTA)
Background/Purpose: The pattern of arterial involvement and disease severity varies in those affected with cTA. Distinct imaging patterns that have some congruence with clinical phenotype…Abstract Number: 062 • 2020 Pediatric Rheumatology Symposium
Is Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) a Reliable Tool for Detecting Vascular Activity in Treated Childhood-Onset Takayasu’s Arteritis (C-TA)? A Multicenter Study
Background/Purpose: The improving therapeutic approach towards childhood-onset Takayasu’s arteritis (c-TA) has decreased the mortality rate over the years and increased concerns on how to improve…Abstract Number: 106 • 2020 Pediatric Rheumatology Symposium
Childhood-onset Takayasu Arteritis: A Single Center Case Series of Atypical and Varied Presentations
Background/Purpose: Childhood-onset Takayasu arteritis is a rare inflammatory vessel disease that predominantly affects the aorta and its major branches. Clinical presentation at disease onset can…Abstract Number: 15 • 2019 ACR/ARP Annual Meeting
CYR61/TGF-β Axis Promotes Adventitial Fibrosis of Takayasu Arteritis in the IL-17 Mediated Inflammatory Microenvironment
Background/Purpose: As a novel proinflammatory and potential profibrotic factor, the role of CYR61 on the vascular fibrosis of Takayasu arteritis (TA) has not been investigated.Methods:…Abstract Number: 741 • 2019 ACR/ARP Annual Meeting
Vascular Damage Is Less Present in an Early Inception Cohort in Takayasu’s Arteritis
Background/Purpose: There is only retrospective and very limited data for the long term prognosis of Takayasu's Arteritis (TAK), a rare large-vessel vasculitis. In this study,…Abstract Number: 743 • 2019 ACR/ARP Annual Meeting
Association Between Acute-phase Reactants, interleukin-6(IL6), Tumor Necrosis Factor-a(TNFa) and Disease Activity in Takayasu’s Arteritis During Follow-up with Repeated Evaluation of Vascular Imaging Manifestations
Background/Purpose: To investigate the laboratory indicators of disease activity during follow-up of Takayasu’s arteritis(TAK).Methods: Electronic data of 588 patients with TAK enrolled in the Chinese…Abstract Number: 746 • 2019 ACR/ARP Annual Meeting
Childhood-Onset Takayasu’s Arteritis (TAK) Is Clinically More Active, However Has Similar Cumulative Damage Compared to Adult-Onset TAK
Background/Purpose: Childhood-onset Takayasu’s Arteritis (TAK) may differ in presentation, clinical manifestations and treatment, as previously shown1. We aimed to compare the clinical manifestations, vascular involvement…Abstract Number: 748 • 2019 ACR/ARP Annual Meeting
Takayasu Arteritis and Sacroiliitis: A Case Control Study in 28 Patients of a Single Italian Center
Background/Purpose: A lot of clinical case descriptions about spondyloarthropathy in TAK patients were reported. Recently, a paper about an increased incidence of spondyloarthropathy in TAK…Abstract Number: 752 • 2019 ACR/ARP Annual Meeting
Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis
Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis affecting mainly young women. Biologic agents are currently use to treat refractory TA patients but no…Abstract Number: 753 • 2019 ACR/ARP Annual Meeting
Initial Clinical Presentation Is Associated with Outcome in Takayasu’s Arteritis
Background/Purpose: The natural history of Takayasu’s arteritis (TAK) remains poorly characterized. A “triphasic” pattern of disease has been proposed where constitutional symptoms precede vascular inflammation…Abstract Number: 757 • 2019 ACR/ARP Annual Meeting
Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis
Background/Purpose: Takayasu arteritis (TAK) occurs at a young age and has a long-term clinical course. Progression of arterial stenosis or dilatation leads to organ dysfunction.…Abstract Number: 763 • 2019 ACR/ARP Annual Meeting
Treatment Efficacy Evaluation of Leflunomide by Regulating Macrophages in Takayasu Arteritis
Background/Purpose: To evaluate the efficacy and safety of leflunomide (LEF) for active Chinese Takayasu Arteritis (TA) patients in induction therapy compared with cyclophosphamide (CYC) and…Abstract Number: 764 • 2019 ACR/ARP Annual Meeting
The Clinical and Angiographic Features of Chinese Takayasu’s Arteritis Patients: A Cohort Study of 591 Patients in 6 Years
Background/Purpose: To investigate the clinical and angiographic features of 591 Chinese Takayasu’s arteritis (TAK) patientsMethods: Clinical and angiographic findings of 591 Chinese TAK patients enrolled…Abstract Number: 769 • 2019 ACR/ARP Annual Meeting
Damage in Takayasu‘s Arteritis Is Associated with Age at Symptom-onset, Disease-duration and Corticosteroid Dose but Not Relapse in Routine Follow-up
Background/Purpose: As a large-vessel vasculitis of young-age group, Takayasu‘s arteritis (TAK) have a high morbidity and mortality caused by the disease or treatments such as…Abstract Number: 770 • 2019 ACR/ARP Annual Meeting
Involvement of Iliofemoral and Axillary Arteries in PET-CT May Be Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis
Background/Purpose: FDG-PET-CT is recommended as one of the imaging modalities for the diagnosis and monitoring of primary large-vessel vasculitis (LVV), such as Takayasu’s arteritis (TAK).…
ACR Meeting Abstracts